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Abstract
Background: This study determined the effects of a novel combination of vitamin D and probiotic on metabolic
and clinical symptoms in chronic schizophrenia.
Methods: This trial was conducted among 60 patients with chronic schizophrenia to receive either 50,000 IU vitamin
D3 every 2 weeks plus 8 × 109 CFU/day probiotic (n = 30) or placebo (n = 30) for 12 weeks.
Results: Vitamin D and probiotic co-supplementation was associated with a significant improvement in the
general (− 3.1 ± 4.7 vs. + 0.3 ± 3.9, P = 0.004) and total PANSS scores (− 7.4 ± 8.7 vs. -1.9 ± 7.5, P = 0.01). Vitamin
D and probiotic co-supplementation also significantly increased total antioxidant capacity (+ 51.1 ± 129.7 vs.
-20.7 ± 53.3 mmol/L, P = 0.007), and significantly decreased malondialdehyde (− 0.3 ± 0.9 vs. + 0.2 ± 0.4 μmol/L, P
= 0.01) and high sensitivity C-reactive protein levels (− 2.3 ± 3.0 vs. -0.3 ± 0.8 mg/L, P = 0.001) compared with
the placebo. Moreover, taking vitamin D plus probiotic significantly reduced fasting plasma glucose (− 7.0 ± 9.9
vs. -0.2 ± 9.9 mg/dL, P = 0.01), insulin concentrations (− 2.7 ± 2.3 vs. + 0.4 ± 2.0 μIU/mL, P < 0.001), homeostasis
model of assessment-estimated insulin resistance (− 0.8 ± 0.7 vs. + 0.1 ± 0.7, P < 0.001), triglycerides (− 7.8 ± 25.2
vs. + 10.1 ± 30.8 mg/dL, P = 0.01) and total cholesterol levels (− 4.9 ± 15.0 vs. + 5.9 ± 19.5 mg/dL, P = 0.04) and
total−/HDL-cholesterol ratio (− 0.1 ± 0.6 vs. + 0.3 ± 0.8, P = 0.04).
Conclusion: Probiotic and vitamin D for 12 weeks to chronic schizophrenia had beneficial effects on the
general and total PANSS score, and metabolic profiles.
Trial Registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for clinical
trials registration (http://www.irct.ir: IRCT2017072333551N2). 07-31-2017 2
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Background
Over 50 million people around the world suffer from
schizophrenia [1]. It is the most disabling and costly
chronic condition because treatment-resistant symptoms
are very common [2]. Schizophrenia is a highly destruc-
tive illness characterized by recurrent relapses, cognitive
decline, emotional and functional disability [3]. This dis-
ease consists of positive (hallucinations, delusions) and
negative (emotional blunting, apathy) symptoms, and
cognitive impairment, the two latter ones very resistant
to antipsychotic medication [4]. With present alterations
emerge to only show a modest benefit or do more disad-
vantage than good [5, 6], due to their side impacts and
tolerance, there are calls to reconsider the impact that
nutrition could have on mental disorders [7, 8]. In
addition, metabolic disturbances including insulin resist-
ance and dyslipidemia are related to cognitive impair-
ment in schizophrenia which could help to functional
decline found in these subjects [9].
It has been shown that crosstalk between nutrition
and mental health is associated with neurotransmitter
and hormonal pathways in the gut which regulate the
function of brain [7]. Low levels Vitamin D is highly
prevalent in schizophrenic patients [10, 11] and vitamin
D supplementation might improve clinical and meta-
bolic profiles in neuropsychiatric disorders, though
* Correspondence: asemi_r@yahoo.com
8Research Center for Biochemistry and Nutrition in Metabolic Diseases,
Kashan University of Medical Sciences, Kashan, I.R, Iran
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ghaderi et al. BMC Psychiatry           (2019) 19:77 
https://doi.org/10.1186/s12888-019-2059-x
available results are controversial. In a study, McGrath
and colleagues [12] revealed that the supplementation of
vitamin D could reduce the risk of schizophrenia at a
dosage of at least 2000 IU/day in males in the first year
of life. In a study conducted by Humble et al. [13], 85%
of the 117 psychiatric subjects had suboptimal vitamin
D status; interestingly the lowest level was for schizo-
phrenic patients. The patients receiving vitamin D sup-
plements achieved considerable improvement in their
psychosis and depression symptoms [13]. However, vita-
min D supplementation at a dosage of 1000 IU/day
showed no changes in psychiatric symptoms [14]. More-
over, neuropsychiatric disorders, including schizophrenia
and depression might be modulated by change in the ex-
ogenous probiotics and microbial substrates [15]. Pro-
biotic supplementation for 14 weeks prevented common
somatic symptoms of disease among outpatients with
schizophrenia, yet did not affect the PANSS [16]. The
single nutrient treatments including probiotic or vitamin
D in the neuropsychiatric diseases show a modest sign
enhancement or null findings [14, 16]. To date, there is
a growing appeal to employ the combination platforms
(e.g., vitamin D plus probiotics), particularly in subjects
with vitamin D deficiency that could ameliorate symp-
toms in a number of mental psychiatric illnesses. The
basis of this approach relies on probiotics effect on in-
creasing vitamin D levels [17, 18].
Aims of the study
Given the anti-inflammatory, antioxidant and
immune-modulatory impacts of vitamin D and probio-
tics, we hypothesized that their combination might be
beneficial in chronic schizophrenia. Therefore, con-
ducted to evaluate the impacts of vitamin D and pro-
biotic on clinical symptoms, biomarkers of oxidative
stress and cardiometabolic risk in chronic schizophrenia.
Methods
Study design and population
This randomized, double-blind, placebo-controlled trial
was registered by the Iranian registry of clinical trials
(http://www.irct.ir: # IRCT2017072333551N2). It was
conducted at a psychiatry clinic in Kashan, Iran from
July to October 2017. Any participant who diagnosed
with schizophrenia using DSM-IV-TR criteria with dis-
ease duration of at least two years, had PANSS score of
55 or greater, treated with chlorpromazine (300–1000
mg/day, except clozapine) and agents anticholinergic
(Trihexyphenidyl, 4–8mg/day) during the last 6 months
and aged 25–65 years old were included in the study.
Any subject with mental retardation (Intelligent Quo-
tient of< 70), substance or alcohol addiction (except caf-
feine or nicotine) within the last 6 months of screening,
a score of≥14 on a 17-item Hamilton Depression Rating
Scale or a score of ≥4 on PANSS (depression item), any-
one under treatment with lithium, carbamazepine, sodium
valproic acid, with existing chronic and acute medical ill-
ness, with lactation or pregnancy, the use of antidepres-
sants including MAO, TCA, SSRI in the last 6months
were excluded from this trials. Study protocol followed
the principals of the Declaration of Helsinki and was ap-
proved by the ethics committee at Kashan University of
Medical Sciences (KAUMS) (No. IR.KAUMS.-
REC.1396.10). Informed consent was signed by all partici-
pants prior to the intervention.
Clinical trial procedures
Computer-generated random numbers were used by an
instructed staff to randomize study participants at the
psychiatry clinic. While randomizing, age (< 65 vs. ≥65 y),
gender (male vs. female), BMI (< 25 vs. ≥25 kg/m2) and
type and dosage of psychiatric medications were taken
into consideration. Then, participants were equally allo-
cated into either taking 50,000 IU of vitamin D3 every 2
weeks plus 8 × 109 CFU/day of probiotic supplements
containing Lactobacillus acidophilus, Bifidobacterium bifi-
dum, Lactobacillus reuteri, and Lactobacillus fermentum
(each 2 × 109) for 12 weeks (treatment group, n = 30) or
placebo which were capsules in the similar shape and
packaging as vitamin D and probiotic (placebo group, n =
30). Participants were instructed not taking other vitamin
D and probiotic supplements, while maintaining their
regular diet and physical activity during the trial. Placebos,
vitamin D, and probiotic were produced by Zahravi
Pharmaceutical Company (Tabriz, Iran), LactoCare®, Zist-
takhmir Company (Tehran, Iran) and Barij Essence
Pharmaceutical Company (Kashan, Iran), respectively.
Study compliance was determined by counting the
remaining tablets in the returned containers as well as
measuring serum 25-OH-vitamin D concentration. All
participants were asked to record their food intake for 3
days (one and two weekdays) at week 1, 5, 9 and 12 of the
trial. These recorded data were used to calculate partici-
pants’ nutrient intake for the Iranian food pattern. Phys-
ical activity was assessed through participants’ physical
activity record at the first day of each month [19].
Assessment
Biometric measures
The Height and weight of subjects were obtained with-
out shoes and in light clothing by a trained staff in the
psychiatry clinic at baseline and the end of the interven-
tion. Body Mass Index (BMI) was reached as weight in
kg divided by height in square meter.
Clinical measures
Severity of psychiatric symptoms was assessed using
PANSS [20] and different domains of cognitive function
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were evaluated through BPRS scores [21]. These tests
are routinely used for the assessment of cognition in
schizophrenia in psychiatric settings worldwide. The
PANSS is a 30-items rating scale composing of validated
subscales to assess negative (7 items), positive (7 items),
and general psychopathological (16 items) signs of
schizophrenia. These 3 subscales are summed up in the
PANSS total score [20]. BPRS was through using chart
review and semi-structured clinical interview for
DSM-IV-TR [21].
Biochemical measures
Fasting blood (10 mL) were collected from study partici-
pants at the beginning and after the 12-week interven-
tion at Kashan reference laboratory (Kashan, Iran).
Serum 25-hydroxyvitamin D concentrations were mea-
sured using an ELISA kit (IDS, Boldon, UK) with inter-
and intra-assay coefficient of variations (CVs) below 7%.
Total antioxidant capacity (TAC) concentrations were
measured using the method of ferric reduction antioxi-
dant power developed by Benzie and Strain [22]. Total
glutathione (GSH) and malondialdehyde (MDA) concen-
trations also were measured using Beutler method [23]
and thiobarbituric acid reactive substances spectro-
photometric test, respectively [24]. CVs for plasma TAC,
GSH and MDA were less than 5%. Serum
high-sensitivity C-reactive protein (hs-CRP) levels were
determined by commercial ELISA kit (LDN, Nordhorn,
Germany) with inter- and intra-assay CVs below 7%. Ni-
tric oxide (NO) levels were measured using Griess
method [25]. Serum insulin concentrations were
assessed through applying an ELISA kit (DiaMetra, Mi-
lano, Italy) with inter- and intra-assay CVs below 5%.
The homeostasis model of assessment-insulin resistance
(HOMA-IR) and the quantitative insulin sensitivity
check index (QUICKI) were calculated using standard
formula [26]. Enzymatic kits (Pars Azmun, Tehran, Iran)
with intra-assay CVs of less than 5% were applied to
measure fasting plasma glucose (FPG) and lipid profiles.
Statistical analyses
Suggested formula for clinical trial sample size calcula-
tion was used to calculate sample size in this study. Con-
sidering type one (α) and type two errors (β) of 0.05, and
0.20, of the power of study was 80%. According to
Sheikhmoonesi et al. [27], we used positive PANSS score
as the primary outcome with 5.4 as the mean change (d)
and 6.7 as the SD. Based on the sample size calculation,
25 subjects were required for each treatment group;
allowing for 20% dropouts, the final sample size was
considered to be 30 participants in each group.
The Kolmogrov-Smirnov test was employed to check
the normal distribution of data. Intention-to-treat (ITT)
analysis was applied for all randomly allocated cases.
Independent samples t-test was performed to compare
the differences in baseline characteristics and daily diet-
ary macro- and micro-nutrient intakes between the two
treatment groups. Pearson Chi-square test was con-
ducted for the comparison of categorical variables. To
assess the impacts of vitamin D and probiotic on clinical
symptoms, biomarkers of inflammation and oxidative
stress, lipid profiles, insulin metabolism and repeated
measures analysis of variance (RM ANOVA) was used.
To control confounding variables, such as baseline
values of each biochemical variable, age and baseline
BMI, we were done analysis of covariance (ANCOVA).
Significance level was the p-value of less than 0.05. Stat-
istical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA) was applied to run all statistical
analyses in this study.
Results
Four participants in the placebo groups and supple-
mented dropped out (Fig. 1). However, 60 participants
were included in the final analysis using ITT methods.
Generally, the compliance rate was high, because of
more than 90% of capsules were consumed throughout
the study in both groups and 25-hydroxyvitamin D levels
significantly elevated in supplemented group.
There was no significant difference between the two
groups in terms of height, age, weight, BMI and METs
at baseline as well as mean changes in weight and BMI
throughout the trial (Table 1).
Based on 3-days dietary records, we observed no sig-
nificant difference in dietary energy, protein, carbohy-
drate, saturated fatty acids, fat, polyunsaturated fatty
acids, monounsaturated fatty acids, total dietary fiber,
cholesterol and micronutrients (Table 2).
After the 12-week intervention, vitamin D and pro-
biotic led to a significant enhancement in
25-OH-vitamin D levels (+ 9.1 ± 4.1 vs. + 0.2 ± 0.4 ng/
mL, P < 0.001), the general (− 3.1 ± 4.7 vs. + 0.3 ± 3.9, P
= 0.004) and total PANSS score (− 7.4 ± 8.7 vs. -1.9 ± 7.5,
P = 0.01) (Table 3). In addition, probiotic and vitamin D
significantly increased plasma TAC (+ 51.1 ± 129.7 vs.
-20.7 ± 53.3 mmol/L, P = 0.007), and decreased MDA (−
0.3 ± 0.9 vs. + 0.2 ± 0.4 μmol/L, P = 0.01) and serum
hs-CRP levels (− 2.3 ± 3.0 vs. -0.3 ± 0.8 mg/L, P = 0.001).
Moreover, taking vitamin D plus probiotic, significantly
reduced FPG (− 7.0 ± 9.9 vs. -0.2 ± 9.9 mg/dL, P = 0.01),
serum insulin concentrations (− 2.7 ± 2.3 vs. + 0.4 ± 2.0
μIU/mL, P < 0.001), HOMA-IR (− 0.8 ± 0.7 vs. + 0.1 ±
0.7, P < 0.001), triglycerides (− 7.8 ± 25.2 vs. + 10.1 ± 30.8
mg/dL, P = 0.01), total- (− 4.9 ± 15.0 vs. + 5.9 ± 19.5 mg/
dL, P = 0.04), and total−/HDL-cholesterol ratio (− 0.1 ±
0.6 vs. + 0.3 ± 0.8, P = 0.04). Vitamin D and probiotic
co-supplementation also significantly increased QUICKI
(+ 0.02 ± 0.01 vs. + 0.0003 ± 0.01, P < 0.001). Taking
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vitamin D and probiotic had no significant effect on
BPRS score and other metabolic profiles. Linear regres-
sion analysis revealed no association between serum
25-OH-vitamin D status and PANSS score at study base-
line (β = 0.05, P = 0.16).
There was observed a statically difference in the baseline
levels of positive PANSS score (P=0.009), BPRS (P< 0.001),
GSH (P= 0.002) and plasma NO (P< 0.001). Hence, we ad-
justed the analysis for baseline values of biochemical parame-
ters, age and baseline BMI. After controlling for these
potential confounders, the difference in changes in total
−/HDL-cholesterol ratio (P=0.06) between the two groups
became non-significant, while difference in changes in negative
PANSS score (P=0.03), BPRS (P= 0.03) and plasma GSH (P
=0.004) became statistically significant (Table 4). Other meta-
bolic profiles did not change statically after this adjustment.
Discussion
We found that probiotic and vitamin D for 12 weeks to
patients with chronic schizophrenia had ameliorated
Fig. 1 Summary of patient flow diagram
Table 1 General characteristics of study participants at baseline study
Placebo group
(n = 30)
Vitamin D plus probiotic group
(n = 30)
P1
Age (y) 43.2 ± 6.0 44.8 ± 8.3 0.41
Gender
Female 2 (6.7) 2 (6.7) > 0.99†
Male 28 (93.3) 28 (93.3)
Height (m) 168.6 ± 7.5 170.6 ± 6.0 0.24
Weight at study baseline (kg) 69.5 ± 10.7 67.2 ± 9.0 0.38
Weight at end-of-trial (kg) 69.5 ± 10.5 67.5 ± 8.7 0.42
Body weight change (kg) 0.04 ± 0.7 0.2 ± 1.2 0.43
BMI at study baseline (kg/m2) 24.5 ± 3.7 23.1 ± 2.8 0.11
BMI at end-of-trial (kg/m2) 24.5 ± 3.7 23.2 ± 2.7 0.12
BMI change (kg/m2) 0.01 ± 0.2 0.1 ± 0.4 0.46
Data are means± SDs
1Obtained from independent samples t-test
†Obtained from Fisher’s exact test
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effects on the general and total PANSS scores, as well as
their metabolic profiles. This clinical trial reporting the ef-
fect of vitamin D and probiotic on clinical symptoms, bio-
markers of oxidative stress and inflammation, lipid
profiles and glycemic control in chronic schizophrenia. In
current study, all patients were being hospitalized during
the intervention; otherwise there was no difference in
treatment protocol between outpatient and inpatient. The
only difference might be the compliance rate which was
closely monitored for inpatients. Moreover, to our best
knowledge, the overall treatment protocol for schizo-
phrenic patients is similar around globe. So, this study can
be generalized to other countries as well. It should be
taken into account that there was a significant difference
in positive PANSS score and BPRS between placebo and
vitamin D plus probiotic groups at study baseline. There
are several reasons to explain this difference. In the
current study, we did not randomize subjects based on
their PANSS score and BPRS due to being diagnosed with
chronic schizophrenia. Random allocation into two groups
was done after stratification for age (< 65 vs. ≥65 y), gen-
der (female vs. male) and pre-intervention BMI (< 25 vs.
≥25 kg/m2) by using computer random numbers. There-
fore, the difference in positive PANSS score and BPRS
existing in both groups occurred by chance. In the current
study, there was no significant difference between two
intervention groups in terms of weight and BMI after
12-week intervention. Further studies are required to
examine the effects of probiotic and vitamin D on weight,
BMI and metabolic outcomes in schizophrenia, consider-
ing longer duration, which may affect clinical symptoms.
Effect on clinical signs
The current study showed that probiotic and vitamin D
for 12 weeks to patients with chronic schizophrenia sig-
nificantly ameliorated general and total PANSS scores,
but did not impacts negative and positive PANSS scores,
as well as BPRS score. Lack of significant effect of vita-
min D and probiotic co-supplementation on BPRS and
PANSS Positive subscales may be due to baseline values
of measured PANSS subscales and BPRS, baseline status
of 25-OH-vitamin D, different dosages and type of vita-
min D and probiotic used. In order to improve BPRS
and PANSS Positive subscales, individuals might need
higher doses of vitamin D plus probiotic supplementa-
tion for a longer period of time to provide appropriate
circulating levels for improving BPRS. Numerous evi-
dences have reported that vitamin D deficiency remains
a widespread difficulty in chronic schizophrenic [28–31].
Several risk factors for schizophrenia, including latitude,
migration and season of birth, have been associated with
vitamin D deficiency [28]. Furthermore, metabolic disor-
ders such as diabetes, insulin resistance, obesity, cardio-
vascular disease and hyperlipidaemia, which are
commonly show in chronic schizophrenic, might be re-
lated to low levels vitamin D. Serotonin, as one of the
major neurotransmitters, has a crucial task in the func-
tion of brain [32]. Vitamin D, which controls more than
900 genes in the body, regulates brain serotonin synthe-
sis through activating tryptophan hydroxylase 2 [33].
Low concentration of 25(OH)D in serum have been re-
lated to an elevated risk of attention deficit hyperactivity
disease, schizophrenia, bipolar disorder, antisocial, and
Table 2 Mean dietary intakes of study participants at baseline, weeks 5, 9 and 12 of the study1
Placebo group
(n = 30)
Vitamin D plus probiotic group
(n = 30)
P2
Energy (kcal/d) 2540 ± 184 2488 ± 147 0.23
Carbohydrates (g/d) 347.9 ± 42.1 337.9 ± 43.2 0.36
Protein (g/d) 89.5 ± 12.9 85.7 ± 11.2 0.23
Fat (g/d) 92.6 ± 13.4 92.2 ± 12.2 0.91
SFAs (g/d) 26.4 ± 5.6 26.3 ± 5.8 0.85
PUFAs (g/d) 30.0 ± 8.4 28.9 ± 6.9 0.61
MUFAs (g/d) 25.0 ± 5.6 24.4 ± 5.8 0.68
Cholesterol (mg/d) 188.6 ± 97.0 222.6 ± 119.7 0.18
TDF (g/d) 20.7 ± 5.2 18.9 ± 4.8 0.18
Magnesium (mg/d) 325.1 ± 88.3 295.8 ± 69.7 0.15
Zinc (mg/d) 11.1 ± 3.0 10.4 ± 2.8 0.34
Manganese (mg/d) 2.4 ± 0.8 2.3 ± 0.6 0.44
Calcium (mg/d) 1203.1 ± 161.9 1145.6 ± 231.3 0.27
Vitamin D (μg/d) 2.8 ± 0.7 2.6 ± 0.5 0.24
1Data are means± SDs
2Obtained from independent t-test
MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; SFAs, saturated fatty acids; TDF, total dietary fiber
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impulsive behavior [34, 35]. Available data suggest that
4000 IU/day of vitamin D may be able decrease the inci-
dence of vitamin D deficiency and help decrease the risk
of psychiatric diseases and improve brain function [36].
In another study, vitamin D supplementation to chronic
schizophrenic patients, at a dosage of 14,000 IU bi-
weekly, for 18 weeks was related a trend towards en-
hanced cognition, but did not influence psychosis,
metabolic status or mood [37]. Probiotic microorgan-
isms change the balance of gut microbiota and prevent
abnormal responses to harmful food-derived antigens
[38]. Schizophrenia is one of the diseases with increased
levels of antibodies to food antigens [39]. Moreover,
gastrointestinal issues such as constipation are very
common in schizophrenic patients as the side effect of
their medications and probiotics improve bowel function
[40, 41]. Probiotics also modulate the inflammatory re-
sponse and oxidative stress in the body [38, 42], which is
one of the major pathologic grounds in schizophrenia
[43]. These are the main reasons probiotics have been
recommended in schizophrenic patients. There are ani-
mal studies showing that probiotic supplementation
might change cognitive and behavioral abnormalities in
sick animals [44, 45]; however, human studies are scarce.
Current controversial evidence could be stated by differ-
ent dosages of probiotics, various study designs, and
vitamin D applied along with participants’ characteris-
tics. The significant association between vitamin D defi-
ciency and higher risk of schizophrenia has already been
proved and the evidence regarding the modest impact of
vitamin D supplementation on clinical symptoms of
schizophrenia is there, however the magnitude was
dependent upon an optimal background of other nutri-
ents and helpful microbiota. Optimal vitamin D levels
are requiring for nearly every cell; it is but one of the
components required for proper functioning of all meta-
bolic processed of the body. Multiple lines evidence pro-
posing synergistic effect of combined vitamin D and
Table 3 Clinical symptoms, biomarkers of oxidative stress and cardio-metabolic risk at baseline and after the 12-week intervention in
patients with schizophrenia
Placebo group (n = 30) Vitamin D plus probiotic group (n = 30) P1
Baseline End-of-trial Change Baseline End-of-trial Change
PANSS subscales
Negative 29.1 ± 4.7 27.0 ± 3.8 −2.1 ± 3.7 27.8 ± 3.5 23.9 ± 5.0 −3.8 ± 4.1 0.08
Positive 19.4 ± 4.9 19.3 ± 5.3 −0.1 ± 2.8 22.8 ± 4.7 22.3 ± 4.8 −0.5 ± 3.8 0.64
General 38.9 ± 10.8 39.2 ± 9.5 0.3 ± 3.9 34.8 ± 6.4 31.7 ± 5.7 −3.1 ± 4.7 0.004
Total 87.5 ± 15.5 85.5 ± 14.1 −1.9 ± 7.5 85.4 ± 10.3 78.0 ± 11.3 −7.4 ± 8.7 0.01
BPRS 68.1 ± 9.7 68.5 ± 7.7 0.3 ± 4.9 58.5 ± 10.1 58.5 ± 10.2 0.0 ± 12.3 0.89
25-OH-vitamin D (ng/mL) 13.7 ± 3.2 13.9 ± 3.3 0.2 ± 0.5 15.0 ± 4.1 24.2 ± 5.3 9.1 ± 4.1 < 0.001
TAC (mmol/L) 1012.5 ± 208.6 991.7 ± 189.0 −20.7 ± 53.3 1014.1 ± 143.3 1065.3 ± 142.0 51.1 ± 129.7 0.007
GSH (μmol/L) 591.9 ± 103.2 627.3 ± 106.5 35.3 ± 93.8 681.3 ± 106.5 770.2 ± 129.3 88.9 ± 128.0 0.07
MDA (μmol/L) 2.5 ± 0.8 2.7 ± 0.7 0.2 ± 0.4 2.5 ± 0.9 2.2 ± 0.5 −0.3 ± 0.9 0.01
hs-CRP (mg/L) 4.6 ± 1.5 4.3 ± 1.7 −0.3 ± 0.8 4.3 ± 2.7 2.0 ± 1.5 −2.3 ± 3.0 0.001
NO (μmol/L) 37.8 ± 2.3 38.6 ± 2.7 0.9 ± 2.0 42.2 ± 4.0 42.6 ± 5.3 0.4 ± 3.0 0.43
FPG (mg/dL) 93.2 ± 9.4 93.0 ± 8.7 −0.2 ± 9.9 95.0 ± 10.5 88.0 ± 11.2 −7.0 ± 9.9 0.01
Insulin (μIU/mL) 12.1 ± 2.0 12.5 ± 2.7 0.4 ± 2.0 12.5 ± 3.7 9.8 ± 3.7 −2.7 ± 2.3 < 0.001
HOMA-IR 2.8 ± 0.5 2.9 ± 0.7 0.1 ± 0.7 2.9 ± 0.9 2.1 ± 0.8 −0.8 ± 0.7 < 0.001
QUICKI 0.32 ± 0.009 0.32 ± 0.01 0.0003 ± 0.01 0.32 ± 0.02 0.34 ± 0.02 0.02 ± 0.01 < 0.001
Triglycerides (mg/dL) 154.9 ± 62.2 165.0 ± 62.2 10.1 ± 30.8 142.6 ± 59.9 134.9 ± 49.7 −7.8 ± 25.2 0.01
VLDL-cholesterol (mg/dL) 31.0 ± 12.4 33.0 ± 12.4 2.0 ± 6.1 28.5 ± 11.9 27.0 ± 9.9 −1.5 ± 5.1 0.01
Total cholesterol (mg/dL) 172.6 ± 40.2 178.5 ± 35.8 5.9 ± 19.5 166.7 ± 35.9 161.8 ± 36.7 −4.9 ± 15.0 0.01
LDL-cholesterol (mg/dL) 101.2 ± 35.1 106.2 ± 32.5 5.0 ± 15.8 99.7 ± 28.2 96.6 ± 31.1 −3.0 ± 13.9 0.04
HDL-cholesterol (mg/dL) 40.4 ± 6.0 39.3 ± 6.3 −1.2 ± 6.3 38.5 ± 7.9 38.2 ± 9.2 −0.3 ± 5.7 0.59
Total−/HDL-cholesterol ratio 4.4 ± 1.3 4.7 ± 1.2 0.3 ± 0.8 4.4 ± 1.1 4.3 ± 1.2 −0.1 ± 0.6 0.04
All values are means± SDs
1P values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA)
BPRS Brief Psychiatric Rating Scale; FPG Fasting plasma glucose; GSH Total glutathione; HOMA-IR Homeostasis model of assessment-estimated insulin resistance; hs-
CRP High-sensitivity C-reactive protein; MDA Malondialdehyde; NO Nitric oxide; PANSS Positive and Negative Syndrome Scale; QUICKI Quantitative insulin
sensitivity check index; TAC Total antioxidant capacity
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administration of probiotic on clinical signs and meta-
bolic diseases of subjects detected with schizophrenia.
The basis of this approach relies on probiotics impact
on elevating vitamin D concentrations [46]. Moreover,
probiotics could have synergistic impacts with vitamin
D, via enhancing vitamin D receptors expression [47].
Effect on oxidative stress and inflammation
This study documented, taking probiotics and vitamin
D for 12 weeks by patients with chronic schizophrenia
significantly enhanced plasma TAC, and significantly
reduced serum hs-CRP levels and plasma MDA, but
did not affect TAC. Schizophrenia is associated with
oxidative stress, inflammation and impaired antioxi-
dant defense [46]. In healthy population and in those
with different chronic diseases like diabetes, athero-
sclerosis and polyarthritis, the higher concentrations
of 25(OH)D have been correlated with lower status of
inflammatory biomarkers including interleukin 6, CRP,
and tumor necrosis factor alpha [47, 48]. In a group
of diabetic patients on hemodialysis, who were
severely vitamin D deficient, inflammatory markers
significantly decreased after 12 weeks of vitamin D
supplementation [49]. In another study conducted by
Anandabaskar et al. [50], high-dose vitamin D intake
significantly improved reduced oxidative stress and
vascular functions in type 2 diabetic patients. Similar
impact has been shown in patients with MDD [51].
This effect might be influenced by different scales like
disease condition, vitamin D dose, obesity and other
nutrients status. Mousa et al. [52] did not find any
lowering effect of vitamin D supplement on inflam-
mation in obese adults supplemented with 4000 IU/
day vitamin D for 16 weeks. The impacts of probiotics
on oxidative stress and inflammation are controver-
sial. Lactobacillus casei supplementation improved
disease activity and inflammatory [53], though
Mohammadi et al. [54] did not find any lowering ef-
fect of probiotics on inflammatory and oxidative
stress markers. This discrepancy was the reason we
speculate the synergistic effect of vitamin D with pro-
biotics might end up with significant results.
Table 4 Adjusted changes in metabolic variables in patients with schizophrenia
Placebo group
(n = 30)
Vitamin D plus probiotics group
(n = 30)
P1
PANSS subscales
Negative −1.9 ± 0.6 −4.0 ± 0.6 0.03
Positive −0.4 ± 0.6 −0.2 ± 0.6 0.82
General 0.7 ± 0.7 −3.5 ± 0.7 < 0.001
Total −1.8 ± 1.4 −7.5 ± 1.4 0.007
BPRS 2.7 ± 1.6 −2.4 ± 1.6 0.03
25-OH-vitamin D (ng/mL) 0.2 ± 0.5 9.1 ± 0.5 < 0.001
TAC (mmol/L) −22.3 ± 17.2 52.7 ± 17.2 0.004
GSH (μmol/L) 16.6 ± 20.4 107.7 ± 20.4 0.004
MDA (μmol/L) 0.2 ± 0.1 −0.3 ± 0.1 < 0.001
hs-CRP (mg/L) −0.2 ± 0.3 −2.4 ± 0.3 < 0.001
NO (μmol/L) 0.8 ± 0.5 0.4 ± 0.5 0.61
FPG (mg/dL) −0.7 ± 1.6 −6.5 ± 1.6 0.01
Insulin (μIU/mL) 0.5 ± 0.4 −2.7 ± 0.4 < 0.001
HOMA-IR 0.1 ± 0.1 −0.8 ± 0.1 < 0.001
QUICKI 0.0001 ± 0.003 0.01 ± 0.003 < 0.001
Triglycerides (mg/dL) 11.5 ± 4.9 −9.1 ± 4.9 0.005
VLDL-cholesterol (mg/dL) 2.3 ± 1.0 −1.8 ± 1.0 0.005
Total cholesterol (mg/dL) 6.6 ± 3.1 −5.6 ± 3.1 0.007
LDL-cholesterol (mg/dL) 5.1 ± 2.7 −3.1 ± 2.7 0.04
HDL-cholesterol (mg/dL) −0.6 ± 1.1 −0.9 ± 1.1 0.87
Total−/HDL-cholesterol ratio 0.3 ± 0.1 −0.04 ± 0.1 0.06
All values are means± SEs. Values are adjusted for baseline values, age and BMI at baseline
1 Obtained from ANCOVA
BPRS Brief Psychiatric Rating Scale; FPG Fasting plasma glucose; GSH Total glutathione; HOMA-IR Homeostasis model of assessment-estimated insulin resistance; hs-
CRP High-sensitivity C-reactive protein; MDA Malondialdehyde; NO Nitric oxide; PANSS Positive and Negative Syndrome Scale; QUICKI Quantitative insulin
sensitivity check index; TAC Total antioxidant capacity
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Effect on metabolic abnormalities
We found that vitamin D and probiotics for 12 weeks to
chronic schizophrenia was related to a significant decrease
in FPG, insulin, HOMA-IR, triglycerides, VLDL-, total-,
LDL- and total−/HDL-cholesterol ratio, and a significant
rise in QUICKI. Metabolic syndrome which is a cluster of
different metabolic abnormalities including abdominal
obesity, dyslipidemia, impaired fasting glucose, hyperten-
sion and or diabetes, is commonly prevalent in schizo-
phrenic. According to National Cholesterol Education
Program (NCEP) criteria, 41% of US in schizophrenia have
metabolic syndrome [55]. Anti-inflammatory function of
vitamin D might potentially decrease the incidence of insu-
lin resistance and obesity in these patients [56, 57]. Among
coronary artery disease, long-term vitamin D supplementa-
tion significantly reduced hyperglycemia and insulin resist-
ance through attenuating oxidative stress and inflammation
[58]. An eight-week pilot study was conducted in schizo-
phrenic patients to assess the short-term impacts of vitamin
D, 2000 IU/day, on their metabolic profile. The authors did
not observe any significant changes in weight, glucose or
lipid profiles. However, patients who had their serum
25(OH)D levels above 30 ng/mL at week 8 achieved a sig-
nificantly greater reduction in total cholesterol levels [59].
Recent reported have depicted that gut microbiota play an
important role in the pathogenesis of metabolic abnormal-
ities and chronic diseases [60]. Probiotics can change gut
flora, improve lipid profiles, and reduce blood glucose level
and insulin resistance [60, 61]. Li et al. [62] showed in their
meta-analysis that probiotic administration promoted gly-
cemic control in diabetic patients. In another study, pro-
biotic supplementation for 8 weeks improved lowered
inflammatory and insulin sensitivity and oxidative stress.
However, did not influence lipid profiles, fasting glucose,
and TAC levels in patients with major depressive disorders
[63, 64]. Nonetheless, Shimizu et al. [65] demonstrated the
lowering effect of probiotics on lipid profiles as a potential
approach for cardiovascular disease prevention. In order to
address this discrepancy, the effect of probiotic and vitamin
D should be taken into account.
This study is related to some limitations. In the
current report, we did not characterize the microbiota
and thus cannot establish whether probiotic adminis-
tration over 12 weeks altered microbiota composition
which leads to funding limitations. In addition, we
could not evaluate an analysis of 16 s RNA of fecal
matter. Therefore, analysis of 16 s RNA of fecal mat-
ter is suggested in future studies. Moreover, one can-
not explain if the treatment impacts found in the
present report was due to the impact of which com-
ponent of the combined supplementation. Hence, fu-
ture research is needed with single supplement in the
present study in order to assess the ameliorate im-
pacts of each supplement on clinical symptoms and
metabolic profiles in chronic schizophrenic patients
with longer duration of supplementation.
Conclusions
Overall, probiotic and vitamin D for 12 weeks to chronic
schizophrenia had impacts effects on the general and
total PANSS scores, as well as their metabolic profiles.
In addition, when we adjusted the analyses for baseline
values, baseline BMI and age, the difference in changes
of negative PANSS score and BPRS became statistically
significant.
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